Efficacy and Safety of Oral Non‐Statin Lipid‐Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta‐Analysis
Tamer Hodrob, Reem J Saad, Aya Hamdy, Mariam Saleh Alheneedy, Ahmed Mohamed Shehata Abdelfattah Elsayed, Elsaghir Ghazy, Hazem Ayesh · 2026
Read Efficacy and Safety of Oral Non‐Statin Lipid‐Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta‐Analysis by Tamer Hodrob, Reem J Saad, Aya Hamdy, Mariam Saleh Alheneedy, Ahmed Mohamed Shehata Abdelfattah Elsayed, Elsaghir Ghazy, Hazem Ayesh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13627895.txt.
Description
Tamer Hodrob and six colleagues compare oral cholesterol-lowering drugs that are not statins, for people whose blood fats stay too high on statins alone or who cannot tolerate them. The team searched four major databases for clinical trials in adults with dyslipidaemia, a condition of unhealthy blood fat levels.
Forty-three trials with more than seventeen thousand participants were combined in a network meta-analysis, a method that compares treatments across separate studies. Drug pairs worked best: obicetrapib with ezetimibe cut LDL cholesterol the most, followed by bempedoic acid with ezetimibe. Side effects were mostly mild, though two drugs saw more people stop treatment, and the authors note that long-term heart outcome trials are still missing.
Catalog record
| CREATOR | Tamer Hodrob, Reem J Saad, Aya Hamdy, Mariam Saleh Alheneedy, Ahmed Mohamed Shehata Abdelfattah Elsayed, Elsaghir Ghazy, Hazem Ayesh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |